vectors protects CNS neurons against neurological insults in vitro and in vivo. J.
Neurosci. 16: 486 – 496.
Linnik, M. D., Zahos, P., Geschwind, M. D., and Federoff, H. J. (1885). Expression of
bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal
cerebral ischemia. Stroke 26: 1670 – 1674; discussion 1675.
Yenari, M. A., et al. (1998). Gene therapy with HSP72 is neuroprotective in rat models
of stroke and epilepsy. Ann. Neurol. 44: 584 – 591.
Ozawa, C. R., et al. (2000). Neuroprotective potential of a viral vector system induced
by a neurological insult. Proc. Natl. Acad. Sci. USA 97: 9270 – 9275.
Mazarakis, N. D., et al. (2001). Rabies virus glycoprotein pseudotyping of lentiviral
vectors enables retrograde axonal transport and access to the nervous system after
peripheral delivery. Hum. Mol. Genet. 10: 2109 – 2121.
Azzouz, M., et al. (2002). Multicistronic lentiviral vector-mediated striatal gene
transfer of aromatic l-amino acid decarboxylase, tyrosine hydroxylase, and GTP
cyclohydrolase I induces sustained transgene expression, dopamine production, and
functional improvement in a rat model of Parkinson's disease. J. Neurosci. 22:
10302 – 10312.
Bienemann, A. S., et al. (2003). Long-term replacement of a mutated nonfunctional
CNS gene: reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral
vector expressing arginine vasopressin. Mol. Ther. 7: 588 – 596.
Monaghan, D. T., Holets, V. R., Toy, D. W., and Cotman, C. W. (1983). Anatomical
distributions of four pharmacologically distinct 3H-l-glutamate binding sites. Nature
306: 176 – 179.
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:
55 – 63.
Schmued, L. C., Albertson, C., and Slikker, W., Jr. (1997). Fluoro-Jade: a novel
fluorochrome for the sensitive and reliable histochemical localization of neuronal
degeneration. Brain Res. 751: 37 – 46.
Schmued, L. C., and Hopkins, K. J. (2000). Fluoro-Jade B: a high affinity fluorescent
marker for the localization of neuronal degeneration. Brain Res. 874: 123 – 130.
Shimazaki, K., Ishida, A., and Kawai, N. (1994). Increase in bcl-2 oncoprotein and the
tolerance to ischemia-induced neuronal death in the gerbil hippocampus. Neurosci.
Res. 20: 95 – 99.
Nilsen, J., and Brinton, R. D. (2003). Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc. Natl. Acad.
Sci. USA 100: 2842 – 2847.
MacDermott, A. B., et al. (1986). NMDA-receptor activation increases cytoplasmic
calcium concentration in cultured spinal cord neurones. Nature 321: 519 – 522.
Hockenbery, D. M., et al. (1993). Bcl-2 functions in an antioxidant pathway to prevent
apoptosis. Cell 75: 241 – 251.
Kane, D. J., et al. (1993). Bcl-2 inhibition of neural death: decreased generation of
reactive oxygen species. Science 262: 1274 – 1277.
Dumuis, A., et al. (1988). NMDA receptors activate the arachidonic acid cascade
system in striatal neurons. Nature 336: 68 – 70.
Lafon-Cazal, M., Pietri, S., Culcasi, M., and Bockaert, J. (1993). NMDA-dependent
superoxide production and neurotoxicity. Nature 364: 535 – 537.
Bonde, C., et al. (2000). GDNF and neublastin protect against NMDA-induced
excitotoxicity in hippocampal slice cultures. Neuroreport 11: 4069 – 4073.
Wang, Y., et al. (2002). Protective effects of glial cell line-derived neurotrophic factor in
ischemic brain injury. Ann. N.Y. Acad. Sci. 962: 423 – 437.
Sarabi, A., Hoffer, B. J., Olson, L., and Morales, M. (2000). GFR alpha-1 is
expressed in parvalbumin GABAergic neurones in the hippocampus. Brain Res. 877:
262 – 270.
Nicole, O., et al. (2001). Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the
mitogen-activated protein kinase pathway. J. Neurosci. 21: 3024 – 3033.
Perrelet, D., et al. (2002). IAPs are essential for GDNF-mediated neuroprotective effects
in injured motor neurons in vivo. Nat. Cell Biol. 4: 175 – 179.
Sawada, H., et al. (2000). Neuroprotective mechanism of glial cell line-derived
neurotrophic factor in mesencephalic neurons. J. Neurochem. 74: 1175 – 1184.
Ralph, G. S., et al. (2004). Identification of potential stroke targets by lentiviral vector
mediated overexpression of HIF-1 alpha and HIF-2 alpha in a primary neuronal model
of hypoxia. J. Cereb. Blood Flow Metab. 24: 245 – 258.
Byrnes, A. P., Rusby, J. E., Wood, M. J., and Charlton, H. M. (1995). Adenovirus gene
transfer causes inflammation in the brain. Neuroscience 66: 1015 – 1024.
Thomas, C. E., et al. (2001). Acute direct adenoviral vector cytotoxicity and chronic,
but not acute, inflammatory responses correlate with decreased vector-mediated
transgene expression in the brain. Mol. Ther. 3: 36 – 46.
McMenamin, M. M., et al. (1998). Potential and limitations of a gamma 34.5 mutant of
herpes simplex 1 as a gene therapy vector in the CNS. Gene Ther. 5: 594 – 604.
Mitrophanous, K., et al. (1999). Stable gene transfer to the nervous system using a nonprimate lentiviral vector. Gene Ther. 6: 1808 – 1818.
Rohll, J. B., et al. (2002). Design, production, safety, evaluation, and clinical
applications of nonprimate lentiviral vectors. Methods Enzymol. 346: 466 – 500.
Martin-Rendon, E., et al. (2002). New methods to titrate EIAV-based lentiviral vectors.
Mol. Ther. 5: 566 – 570
